This week in drug discovery (6-10 June) 

News round-up by DDW’s Reece Armstrong for 6-10 June

Antibiotic developments, vaccines for MMR and business expansions are some of the features of this week’s news round-up.

US gets another MMR vaccine option in GSK’s Priorix  

GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the company has announced.

Nosopharm brings antibiotic one step closer to clinical development

Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections.

Lead Pharma and Oxeltis receive €800K for cancer project  

Two life sciences companies have been awarded an €800K grant for their work developing a small molecule therapy for a fast-growing blood cancer.

Phesi launches digital twin to assist CAR-T development  

Artificial intelligence (AI) solutions provider Phesi has developed a digital twin for Cytokine Release Syndrome (CRS) patients following CAR-T therapy.

SMC opens new pharma business in Cambridge  

Solutions provider SMC Ltd has opened a new business offering pharmaceutical development services at the Cambridge Research Park in the UK.



Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free